Literature DB >> 17660996

Massive subretinal hemorrhage after photodynamic therapy for polypoidal choroidal vasculopathy after macular translocation surgery.

Yoko Fukushima, Fumi Gomi, Masahito Ohji, Yasuo Tano.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17660996     DOI: 10.1007/s10384-007-0444-3

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


× No keyword cloud information.
  5 in total

1.  Successful photodynamic therapy with verteporfin for recurrent choroidal neovascularization beneath the new fovea after macular translocation surgery with 360-degree retinotomy.

Authors:  Miki Sawa; Wai-Man Chan; Masahito Ohji; Kazuyuki Imai; Takashi Fujikado; Yasuo Tano; Andrew P Schachat
Journal:  Am J Ophthalmol       Date:  2003-09       Impact factor: 5.258

2.  Polypoidal choroidal vasculopathy: natural history.

Authors:  Masanobu Uyama; Mitsumasa Wada; Yoshimi Nagai; Takashi Matsubara; Hiroshi Matsunaga; Ichiro Fukushima; Kanji Takahashi; Miyo Matsumura
Journal:  Am J Ophthalmol       Date:  2002-05       Impact factor: 5.258

3.  Translocation of the retina for management of subfoveal choroidal neovascularization I: experimental studies in the rabbit eye.

Authors:  K Imai; A Loewenstein; E de Juan
Journal:  Am J Ophthalmol       Date:  1998-05       Impact factor: 5.258

4.  Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.

Authors:  Wai-Man Chan; Dennis S C Lam; Timothy Y Y Lai; David T L Liu; Kenneth K W Li; Yi Yao; Tak-Hung Wong
Journal:  Ophthalmology       Date:  2004-08       Impact factor: 12.079

5.  Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Authors: 
Journal:  Am J Ophthalmol       Date:  2003-12       Impact factor: 5.258

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.